Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$283.09 +0.8%	$301.29	$253.30 ▼ $346.85	$152.20B	0.59	2.78 million shs	2.08 million shs
GILD Gilead Sciences	$106.34 +3.1%	$109.19	$62.07 ▼ $119.96	$132.41B	0.32	7.48 million shs	9.45 million shs
MAXY Maxygen		$0.00	$0.00 ▼ $0.00	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	$496.49 +0.5%	$490.27	$377.85 ▼ $519.88	$127.49B	0.5	1.33 million shs	1.50 million shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	+0.80%	+3.44%	-7.77%	+1.00%	+4.86%
GILD Gilead Sciences	+3.07%	+1.93%	-4.88%	+13.31%	+62.55%
VRTX Vertex Pharmaceuticals	+0.54%	+3.97%	+0.77%	+12.66%	+24.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	3.9779 of 5 stars	2.2	2.0	3.3	3.9	2.8	2.5	0.6
GILD Gilead Sciences	4.654 of 5 stars	2.4	5.0	2.5	4.1	2.6	2.5	1.9
MAXY Maxygen	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	3.9261 of 5 stars	2.3	4.0	0.0	3.3	2.9	2.5	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.43	Hold	$310.57	9.71% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$109.43	2.91% Upside
MAXY Maxygen	0.00	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	2.64	Moderate Buy	$514.91	3.71% Upside

Current Analyst Ratings Breakdown

Latest MAXY, AMGN, GILD, and VRTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/25/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $135.00
4/25/2025	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$132.00 ➝ $125.00
4/25/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/22/2025	AMGN Amgen	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Neutral	$305.00
4/22/2025	GILD Gilead Sciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$125.00
4/22/2025	VRTX Vertex Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight	$535.00
4/14/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$315.00 ➝ $319.00
4/9/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Equal Weight ➝ Equal Weight	$328.00 ➝ $330.00
4/1/2025	VRTX Vertex Pharmaceuticals	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$408.00 ➝ $420.00
3/31/2025	VRTX Vertex Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$555.00 ➝ $567.00
3/27/2025	GILD Gilead Sciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$120.00 ➝ $130.00

(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$33.42B	4.55	$28.37 per share	9.98	$10.93 per share	25.90
GILD Gilead Sciences	$28.74B	4.61	$8.40 per share	12.66	$15.44 per share	6.89
MAXY Maxygen	N/A	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	$11.02B	11.57	N/A	N/A	$63.90 per share	7.77

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$7.55	37.50	13.23	2.63	12.24%	176.32%	11.71%	5/1/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	287.41	13.11	0.71	1.67%	31.63%	10.38%	N/A
MAXY Maxygen	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	-$535.60M	-$2.20	N/A	28.35	2.11	-4.86%	-2.02%	-1.49%	5/5/2025 (Estimated)

Latest MAXY, AMGN, GILD, and VRTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/5/2025	Q1 2025	VRTX Vertex Pharmaceuticals	$4.24	N/A	N/A	N/A	$2.85 billion	N/A
5/1/2025	Q1 2025	AMGN Amgen	$4.18	N/A	N/A	N/A	$8.05 billion	N/A
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion
2/11/2025	Q4 2024	GILD Gilead Sciences	$1.67	$1.90	+$0.23	$1.42	$7.15 billion	N/A
2/10/2025	Q4 2024	VRTX Vertex Pharmaceuticals	$3.99	$3.54	-$0.45	$3.50	$2.78 billion	N/A
2/4/2025	Q4 2024	AMGN Amgen	$5.04	$5.31	+$0.27	$1.16	$8.87 billion	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.36%	+8.53%	126.09%	14 Years
GILD Gilead Sciences	$3.16	2.97%	+2.74%	66.53%	N/A
MAXY Maxygen	N/A	N/A	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Latest MAXY, AMGN, GILD, and VRTX Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/25/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025
3/4/2025	AMGN Amgen	quarterly	$2.38	3.05%	5/16/2025	5/16/2025	6/6/2025
2/5/2025	GILD Gilead Sciences	quarterly	$0.79	3%	3/14/2025	3/14/2025	3/28/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
GILD Gilead Sciences	1.24	1.50	1.20
MAXY Maxygen	N/A	N/A	N/A
VRTX Vertex Pharmaceuticals	0.01	2.69	2.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
MAXY Maxygen	N/A
VRTX Vertex Pharmaceuticals	90.96%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.69%
GILD Gilead Sciences	0.27%
MAXY Maxygen	N/A
VRTX Vertex Pharmaceuticals	0.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	25,200	537.65 million	533.50 million	Optionable
GILD Gilead Sciences	17,000	1.25 billion	1.24 billion	Optionable
MAXY Maxygen	N/A	N/A	N/A	Not Optionable
VRTX Vertex Pharmaceuticals	4,800	256.79 million	256.28 million	Optionable

MAXY, AMGN, GILD, and VRTX Headlines

Recent News About These Companies

Public Employees Retirement Association of Colorado Trims Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 29 at 7:22 AM | marketbeat.com

Prosperity Consulting Group LLC Sells 661 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 29 at 6:43 AM | marketbeat.com

Johnson Financial Group Inc. Sells 5,283 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 29 at 6:24 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Kovitz Investment Group Partners LLC

April 29 at 5:58 AM | marketbeat.com

Hancock Whitney Corp Cuts Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 29 at 5:48 AM | marketbeat.com

What is Zacks Research's Estimate for VRTX FY2027 Earnings?

April 29 at 2:55 AM | marketbeat.com

What is Zacks Research's Forecast for VRTX FY2027 Earnings?

April 29 at 2:45 AM | americanbankingnews.com

Vertex Pharmaceuticals (VRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

April 28 at 11:05 AM | zacks.com

My 5 Top Stocks to Buy Right Now in This Highly Volatile Market

April 28 at 4:48 AM | fool.com

Zacks Research Analysts Boost Earnings Estimates for VRTX

April 27 at 8:31 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by MGO One Seven LLC

April 27 at 5:39 AM | marketbeat.com

Pinebridge Investments L.P. Trims Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 27 at 5:39 AM | marketbeat.com

Price T Rowe Associates Inc. MD Has $680.85 Million Stock Position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 27 at 5:38 AM | marketbeat.com

Dark Forest Capital Management LP Increases Stock Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 27 at 5:29 AM | marketbeat.com

IHT Wealth Management LLC Sells 747 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 27 at 5:28 AM | marketbeat.com

Q1 EPS Estimate for Vertex Pharmaceuticals Raised by Analyst

April 27 at 3:17 AM | americanbankingnews.com

New medicines recommended for approval by CHMP in April 2025

April 26 at 1:16 PM | thepharmaletter.com

Voya Investment Management LLC Has $281.25 Million Stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

April 26 at 7:11 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Stake Lessened by Banco Bilbao Vizcaya Argentaria S.A.

April 26 at 6:57 AM | marketbeat.com

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Sold by Adage Capital Partners GP L.L.C.

April 26 at 6:24 AM | marketbeat.com

EMA Backs Vertex Pharmaceuticals' (VRTX) Alyftrek for Cystic Fibrosis Treatment | VRTX Stock News

April 25, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MAXY, AMGN, GILD, and VRTX Company Descriptions

Amgen NASDAQ:AMGN

$283.09 +2.25 (+0.80%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$282.48 -0.61 (-0.22%)

As of 08:04 AM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$106.34 +3.17 (+3.07%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$106.26 -0.08 (-0.07%)

As of 08:05 AM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Maxygen NASDAQ:MAXY

Maxygen, Inc. (Maxygen) is a biotechnology company focused on the development of its MAXY-G34 product candidate. MAXY-G34 is a pegylated, granulocyte colony stimulating factor (G-CSF), for the treatment of chemotherapy-induced neutropenia and acute radiation syndrome (ARS). On May 16, 2011, Astellas Pharma Inc. (Astellas) acquired the Company's interests in Perseid Therapeutics LLC, the Company's former subsidiary, which included all of the Company's research and development operations. As a result of the transaction, the Company has reclassified the operating results of Perseid, as well as any related business activities, to discontinued operations. The Company's wholly owned subsidiaries include Maxygen Holdings (U.S.), Inc., Maxygen ApS and Maxygen Holdings, Inc., and its majority owned subsidiary, Maxygen Holdings LLC.

Vertex Pharmaceuticals NASDAQ:VRTX

$496.49 +2.65 (+0.54%)

Closing price 04/28/2025 04:00 PM Eastern

Extended Trading

$497.48 +0.99 (+0.20%)

As of 08:01 AM Eastern

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time